ArticleArthritis research & therapy2012
Risk of end-stage renal disease associated with gout: a nationwide population study.
Article in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies.Arthritis research & therapy · 2015Pooled it
- Increased Risk of Cancer in relation to Gout: A Review of Three Prospective Cohort Studies with 50,358 Subjects.Mediators of inflammation · 2015Pooled it
- Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial.Frontiers in immunology · 2025Trial
- A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.Arthritis & rheumatology (Hoboken, N.J.) · 2023Trial
- Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.BMC research notes · 2014Trial
- Elevated serum cystatin C predicts tophus formation in gout: evidence from a cross-sectional study.Frontiers in endocrinology · 2026Article
- Targeted physical therapy for gouty arthritis: a first-principles frequency-screening study.Frontiers in physiology · 2026Article
- Hyperuricemia, gout and the associated comorbidities in China: findings from a prospective study of 0.5 million adults.The Lancet regional health. Western Pacific · 2025Article
- Impact of Chronic Kidney Disease and Gout on End-Stage Renal Disease in Type 2 Diabetes: Population-Based Cohort Study.Endocrinology and metabolism (Seoul, Korea) · 2024Article
- A consensual machine-learning-assisted QSAR model for effective bioactivity prediction of xanthine oxidase inhibitors using molecular fingerprints.Molecular diversity · 2024Article
- Relationship between gout, hyperuricemia, and obesity-does central obesity play a significant role?-a study based on the NHANES database.Diabetology & metabolic syndrome · 2024Article
- Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update.Cardiology journal · 2024Article
- Comparison Between Early-Onset and Common Gout: A Systematic Literature Review.Rheumatology and therapy · 2023Review
- The Singapore Experience With Uncontrolled Gout: Unmet Needs in the Management of Patients.Cureus · 2023Review
- A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.Arthritis research & therapy · 2022Article
- Evaluation of renal microperfusion in hyperuricemic nephropathy by contrast-enhanced ultrasound imaging.Disease models & mechanisms · 2022Article
- Stroke Risk in Patients with Gout: A Nationwide Retrospective Cohort Study in Taiwan.Journal of clinical medicine · 2022Article
- A glance into the future of gout.Therapeutic advances in musculoskeletal disease · 2022Review
- The risk and severity of stroke in patients with atrial fibrillation and gout: A National Representative Database study.Journal of arrhythmia · 2021Article
- Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.Cardiology journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe explored the risk of end-stage renal disease (ESRD) among gout patients in a representative cohort in Taiwan.
methodsThe primary database used was the Taiwan National Health Insurance Research Database. Subjects older than 20 years without ESRD, coronary heart disease, or stroke were included in the study. The case definition of gout in the present study was gout diagnosis and medical treatment for gout. An ESRD case was defined by the presence of chronic renal failure necessitating long-term renal replacement therapy. Multivariate Cox proportional hazards models were used to evaluate the risk of ESRD among gout patients.
resultsThe analysis included data of 656,108 patients who were followed up for a mean of 8.0 years. Among them, 19,963 (3.0%) patients had gout. At the end of 2008, 2,377 individuals (gout, n = 276; non-gout, n = 2,101) had ESRD, and 861 individuals (gout, n = 77, 27.9%; non-gout, n = 521, 24.8%) died due to ESRD. The rates of incidence of ESRD were 1.73 and 0.41 cases per 1,000 patient-years in the gout and non-gout groups. After adjustment for age, sex, and history of diabetes mellitus and/or hypertension, gout was associated with a hazard ratio (HR) of 1.57 for ESRD (95% confidence interval [CI], 1.38-1.79; P < 0.001). In patients with ESRD, the adjusted HR for death in patients with gout was 0.95 (0.74-1.23, P = 0.71), which was similar to the HR obtained in patients without gout.
conclusionsGout is associated with an increased hazard for development of ESRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.